Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. 2011

Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
Department of Nephrology, Hypertension, Diabetology, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan 960-1295. jyatabe@fmu.ac.jp

Angiotensin II (Ang II) and Ang III stimulate aldosterone secretion by adrenal glomerulosa, but the angiotensin receptor subtypes involved and the effects of Ang IV and Ang (1-7) are not clear. In vitro, different angiotensins were added to rat adrenal glomerulosa, and aldosterone concentration in the medium was measured. Ang II-induced aldosterone release was blocked (30.3 ± 7.1%) by an Ang II type 2 receptor (AT2R) antagonist, PD123319. Candesartan, an Ang II type 1 receptor (AT1R) antagonist, also blocked Ang II-induced aldosterone release (42.9 ± 4.8%). Coadministration of candesartan and PD123319 almost abolished the Ang II-induced aldosterone release. A selective AT2R agonist, CGP42112, was used to confirm the effects of AT2R. CGP42112 increased aldosterone secretion, which was almost completely inhibited by PD123319. In addition to Ang II, Ang III also induced aldosterone release, which was not blocked by candesartan. However, PD123319 blocked 22.4 ± 10.5% of the Ang III-induced aldosterone secretion. Ang IV and Ang (1-7) did not induce adrenal aldosterone secretion. In vivo, both Ang II and Ang III infusion increased plasma aldosterone concentration, but only Ang II elevated blood pressure. Ang IV and Ang (1-7) infusion did not affect blood pressure or aldosterone concentration. In conclusion, this report showed for the first time that AT2R partially mediates Ang III-induced aldosterone release, but not AT1R. Also, over 60% of Ang III-induced aldosterone release may be independent of both AT1R and AT2R. Ang III and AT2R signaling may have a role in the pathophysiology of aldosterone breakthrough.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D000450 Aldosterone A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Aldosterone, (+-)-Isomer,Aldosterone, (11 beta,17 alpha)-Isomer
D000805 Angiotensin III A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%). Des-Asp Angiotensin II,Des-Aspartyl-Angiotensin II,Angiotensin II, Des-Asp,Des Asp Angiotensin II,Des Aspartyl Angiotensin II
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015384 Zona Glomerulosa The narrow subcapsular outer zone of the adrenal cortex. This zone produces a series of enzymes that convert PREGNENOLONE to ALDOSTERONE. The final steps involve three successive oxidations by CYTOCHROME P-450 CYP11B2. Adrenal Glomerulosa,Glomerulosa, Adrenal,Glomerulosa, Zona
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D044139 Receptor, Angiotensin, Type 2 An angiotensin receptor subtype that is expressed at high levels in fetal tissues. Many effects of the angiotensin type 2 receptor such as VASODILATION and sodium loss are the opposite of that of the ANGIOTENSIN TYPE 1 RECEPTOR. Angiotensin II Type 2 Receptor,Angiotensin Type 2 Receptor,Receptor, Angiotensin II Type 2,Angiotensin AT2 Receptor,AT2 Receptor, Angiotensin,Receptor, Angiotensin AT2
D044140 Receptor, Angiotensin, Type 1 An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention. Angiotensin II Type 1 Receptor,Angiotensin Type 1 Receptor,Angiotensin Type 1a Receptor,Angiotensin Type 1b Receptor,Receptor, Angiotensin, Type 1a,Receptor, Angiotensin, Type 1b,Angiotensin AT1 Receptor,Angiotensin AT1a Receptor,Angiotensin AT1b Receptor,Angiotensin II Type 1a Receptor,Angiotensin II Type 1b Receptor,Receptor, Angiotensin II Type 1,Receptor, Angiotensin II Type 1a,Receptor, Angiotensin II Type 1b,AT1 Receptor, Angiotensin,AT1a Receptor, Angiotensin,AT1b Receptor, Angiotensin,Receptor, Angiotensin AT1,Receptor, Angiotensin AT1a,Receptor, Angiotensin AT1b
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
November 1998, Journal of endocrinological investigation,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
April 2013, Peptides,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
July 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
January 1997, Hypertension (Dallas, Tex. : 1979),
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
February 2016, Thrombosis research,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
March 2006, Hypertension (Dallas, Tex. : 1979),
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
July 2000, Journal of cardiovascular pharmacology,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
January 1994, Blood pressure. Supplement,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
January 1998, Endocrine research,
Junichi Yatabe, and Minoru Yoneda, and Midori S Yatabe, and Tsuyoshi Watanabe, and Robin A Felder, and Pedro A Jose, and Hironobu Sanada
August 2011, Neuroscience letters,
Copied contents to your clipboard!